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Background
Juvenile idiopathic arthritis (JIA) is the most common
childhood rheumatological disease with an incidence of 1
in 1000. Methotrexate is the primary DMARD given to
patients with JIA but approximately 30% of children fail
to respond. The SPARKS CHARM study enrolls patients
with JIA about to start MTX with the aim to discover
predictors of response to MTX, to distinguish patients
who will respond well to MTX from non-responders.
Aim
We investigated whether serum levels of inflammatory
proteins such as MRP8/14 could predict JIA responder
status to MTX.
Methods
Blood samples and clinical data including core outcome
variables, were collected pre treatment and at 6 months of
therapy. Serum concentrations of MRP8/14 were deter-
mined by an in-house sandwich ELISA as described (Foell
D, et. al. 2004). The analysing laboratory was blinded for
clinical data. The study had full ethical approval and con-
sent. Response was defined at ACR30, 50,70 levels.
Results
109 patients were included in this study. Patients had
typical frequencies of patient subtypes and MTX
responder status. Systemic patients have known high
levels of MRP8/14, and this was also demonstrated in
our cohort, so were excluded from this analysis. There
were no significant differences between age of onset
between ACR70 and NR patients. MRP8/14 levels were
higher in pre-MTX samples of patients who would go
onto respond to MTX as ACR70 compared to patients
who would not respond. Analysis of ‘intermediate phe-
notype’ patients who would have ACR30 or ACR50
response, revealed that ACR30 had low MRP8/14 levels
comparable to NR and ACR50 levels were similar to
ACR70. The difference between NR/ACR30 and
ACR50/ACR70 in pre-MTX samples was highly signifi-
cant (1495ng/ml vs 2705ng/ml, p=0.008).
Conclusion
These data suggest that MRP8/14 levels are increased in
JIA patients who will go on to respond well to MTX ther-
apy. MRP8/14 is stable without cold storage which will
facilitate delivery of serum samples to specialised labora-
tories for testing. We conclude that used in combination
with routine clinical data, e.g. number of active joints,
M R P 8 / 1 4l e v e l sc o u l dh a v eau s e f u lr o l ei na s s i s t i n gi np r e -
dicting which JIA patients are likely to respond to MTX.
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